Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-R11228 and 177Lu-R11228 in Advanced Breast Cancer
NCT07121244Phase 1Terminated
- Sponsor
- Radionetics Oncology
- Start
- Oct 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of 177Lu-R11228 and 68Ga-R11228 in breast cancer (2 arms), sponsored by Radionetics Oncology. Primary endpoints: Incidence of Adverse Events, Incidence of Serious Adverse Events and 1 more. Started Oct 2025; status: terminated.
02
Drugs
177Lu-R1122868Ga-R11228
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07121244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121244.